LIFELINE NUTRACEUTICALS, INC.

Contact: Bill Driscoll, President/CEO

Tel: 720-488-1711

billdriscoll@lifelinenutraceuticals.com

http://www.lifelinenutraceuticals.com

Lifeline Nutraceuticals, Inc. and CereMedix, Inc. sign an Exclusive Worldwide Licensing Agreement for the development of a novel technology-driven Anti-Aging Dietary Supplement

DENVER, COLORADO AND WORCESTER, MASSACHUSETTS, OCT. 16, 2003. Lifeline Nutraceuticals, Inc. and CereMedix, Inc. announced today that Lifeline has licensed exclusive, worldwide rights to an innovative oral dietary supplement that is being heralded as the first serious product candidate in the battle against oxidative stress. Oxidative stress is widely known to play a key role in over 100 age-related diseases and the aging process itself. This patented and proprietary product, currently known as CMX-1152, has been licensed from its inventor, CereMedix Inc., a Worcester-based biotechnology company. CMX-1152 is one of the products resulting from over 20 years of scientific research by CereMedix founding scientist, Dr. Victor Shashoua and has received much international media and scientific community attention recently as a "break-through" anti-aging product. So significant is this advance in anti-aging technology that a nationally-syndicated television news magazine recently interviewed Lifeline's President, Bill Driscoll, with the intention of publishing a feature story on CMX-1152 in the coming months.

A TRULY UNIQUE APPROACH…

CMX-1152 represents a major leap forward in terms of dietary products designed to deliver anti-oxidants to the human body. Instead of pumping the body full of difficult to digest, largely un-absorbable, and generally ineffective exogenous oxygen scavengers, Lifeline's revolutionary product increases the body's production of its own natural antioxidants using a proprietary, patented peptide derived from a protein that occurs naturally in the human brain. This is believed to be a truly unique approach unlike anything else in the anti-aging, antioxidant field. CMX-1152 acts by mobilizing the body's own "defense and repair" mechanisms, including stimulating the production of the body's primary natural antioxidant enzymes. The result is the rescue of tissues and organs that would otherwise be irrevocably damaged by the effects of oxidative stress.

Independent laboratory analysis has already demonstrated encouraging corroboration of CereMedix's own research, indicating that CMX-1152 up-regulates key antioxidant enzymes by more than 400% above normal levels. In other studies, rats that suffered ischemic strokes were given CMX-1152 and the effects of the strokes were almost completely reversed. Similarly, geriatric mice that received the drug showed significant signs of returning youthfulness. "It's hard to effectively put into words the importance of this licensing agreement for CMX-1152," said Mr. Driscoll. "Lifeline now has the opportunity to develop the solution to a major human need, while also developing a multi-billion dollar product which could bring hope to hundreds of millions of people worldwide who might otherwise prematurely age due to the incredible ravages to their bodies caused by free radicals and oxidation." "We are confident that we have chosen the right partner to effectively bring this unique, revolutionary product to market," said CereMedix President and CEO, Steve Parkinson. "Lifeline has ambitious plans to see that the benefits of CMX-1152 can serve human needs all around the world," Mr. Parkinson continued. "We sought a partner that recognized that CMX-1152 is not like any conventional

dietary supplement and consequently would make this unique platform of using the natural biology of the body to heal itself the focus of its marketing platform." Clinical trials, for CMX-1152 as an over-the-counter oral supplement, are expected to be completed by the end of the first quarter of 2004. Lifeline intends to start marketing the product, under a yet-to-be-determined brand name, in the second quarter of 2004. In the meantime, Lifeline is preparing to take advantage of its very unique competitive advantage in a huge market.